Inhibrx Biosciences (INBX) Stock
Inhibrx Biosciences (INBX) closed at $74.18 on Nov 17, 2026; its Tenet Score is 45 of 100 against 340 Healthcare peers.
39 figures withheld by our checks. Each blank figure names its reason.
Key stats
- Close
- $74.18
- Nov 17, 2026
- Market cap
- $1.1B
- share price × the latest quarter's diluted weighted-average share count (vendor)
- 52-week range
- 57.30 – 155.29
- low → high · as of close, Nov 16, 2026
- Tenet Score
- 45/100
- Mixed · 340 Healthcare peers
Industry: Biological Products, Except Diagnostic Substances
Inhibrx Biosciences Inc. scores 45/100. Mixed. Strongest on financial health, quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 45 is built from 2 of 4 pillars, from 25% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=340Factor grades
Value & Growth omitted — no data yet.
Price
The whole report, at a glance · every card is a live peek, click any to open the section
- ✕ Piotroski F-Score
- ✕ Graham Defensive
- ✕ Drawdown Context
- ✕ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
- ✕ Quality Floor
13F flows & insider trades land here.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate target…
Similar-sized companies in Biological Products, Except Diagnostic Substances
The 1 company in this industry closest in market cap, as of Nov 16, 2026.
| Company | Tenet Score | Market cap |
|---|---|---|
| Cg Oncology Inc.CGON | 52 | $7.5B |
Common questions
What sector and industry is Inhibrx Biosciences in?
Inhibrx Biosciences is in the Healthcare sector and the Biological Products, Except Diagnostic Substances industry.
What is Inhibrx Biosciences' Tenet Score?
Inhibrx Biosciences' Tenet Score is 45 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.




